San Ramon, CA, USA, December 21, 2017 / B3C newswire / -- rfxcel, a global Track & Trace company, has been confirmed as a Technically Certified Connection Provider by the European Medicines Verification Organization (EMVO).
The European Medicines Verification System (EMVS) is a pan-European system operated by EMVO, to enable medicines to be verified at the point of dispensing. Under the terms of the EU Falsified Medicines Directive (FMD) from 9th February 2019, Marketing Authorization Holders within the FMD’s jurisdiction will be required to upload their product serialization data via the EMVS European Hub.
As a Technically Certified Connection Provider, rfxcel will enable Marketing Authorization Holders to capture and report their serialized data and related transactions to the European Hub via a validated, secure and cost-effective solution.
“This marks another major milestone for rfxcel as we continue to grow to meet the traceability and regulatory needs of the pharmaceutical industry in Europe. We are excited to offer the most flexible and feature-rich solution to aid EMVO in its mission to protect the drug supply chain”, said Glenn Abood, CEO of rfxcel.
As the pioneer and leader in traceability solutions for the Life Sciences industry, rfxcel provides its customers with a robust and sophisticated platform with a low total-cost-of-ownership. The EMVO certification – combined with a recent $30M growth capital infusion, the acquisition of Frequentz assets, and important key hires in Europe – widens the Company’s lead as the most versatile player in the industry.
rfxcel is the leading provider of SaaS-based track and trace solutions. Their platform enables companies to protect patients, comply with regulatory mandates, and gain visibility into their supply chain. rfxcel’s relentless commitment to customer success and continuous innovation ensures that companies can meet today’s requirements and tomorrow’s challenges.